Budesonide/formoterol (SYMBICORT) pMDI

DRUG3 trials

Sponsors

AstraZeneca

Conditions

AsthmaChronic Obstructive Pulmonary Disease

Phase 3

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

CompletedNCT00419952

AstraZenecaAsthma

Start: 2007-02-28End: 2009-11-30Updated: 2012-10-30

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

CompletedNCT00419757

AstraZenecaAsthma

Start: 2007-01-31End: 2008-06-30Updated: 2012-08-27

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

CompletedNCT00419744

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2007-01-31End: 2009-08-31Updated: 2010-09-16

Related Papers

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.

2018-01-10303 citations

Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis

2017-09-011 citations

Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.

2015-08-2133 citations

Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: a randomized controlled trial.

2012-04-2514 citations

The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma.

2012-03-013 citations

Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.

2011-10-26110 citations

Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial.

2011-07-146 citations